RUTW240712P2180000
- 24.47
- -127.66-83.92%
Russell 2000 Index Newsroom
Top 5 Financials Stocks That May Collapse This Month
As of July 15, 2024, five stocks in the financials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator,
Patterson-UTI Energy Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 17.88% Piper Sandler $14 → $12 Maintains Overweight 07/11/2024 27.7% Susquehanna $14 → $13
Oil States International Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 27.91% Piper Sandler $7.5 → $5.5 Maintains Neutral 05/06/2024 74.42% Piper Sandler $8 → $7.5
Google-Wiz Deal Would Be 'Shot Across the Bow' at Microsoft, Amazon, Spur M&A: Wedbush
Liberty Energy Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 18.2% Piper Sandler $28 → $25 Maintains Overweight 05/29/2024 51.3% Citigroup $24 → $32
Helmerich & Payne Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 -2.09% Piper Sandler $39 → $36 Maintains Neutral 05/06/2024 6.06% Piper Sandler $44 → $39
This Analyst With 87% Accuracy Rate Sees More Than 12% Upside In AMD - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts
U.S. stocks closed higher on Friday, with the Dow Jones index topping the key 40,000 mark during the session. The 30-stock blue-chip index gained around 1.6% last week.Wall Street analysts make new
Core Laboratories Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 -21.59% Piper Sandler $18 → $17 Maintains Neutral 04/26/2024 -16.97% Stifel $17 → $18
ChampionX Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 0.98% Piper Sandler $40 → $33 Maintains Neutral 04/08/2024 22.4% Piper Sandler $32 → $40
Atlas Energy Solutions Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 28.63% Piper Sandler $29 → $27 Maintains Overweight 05/28/2024 33.4% Goldman Sachs $25 → $28
ANI's Generic L-Glutamine Oral Powder Hits Market, Targets $20.1M Annual Sales
ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (
ProFrac Holding Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 13.78% Piper Sandler $11 → $9 Maintains Overweight 04/15/2024 20.1% B of A Securities $8.5 → $9
Select Medical's Concentra Launches IPO for 22.5M Shares on NYSE
Select Medical Holdings Corporation ("Select Medical") (NYSE:SEM) today announced that Concentra Group Holdings Parent, Inc. ("Concentra"), a wholly owned subsidiary of Select Medical, has launched
Walmart Continues to Add More Restaurant Chains to Its Stores
HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $20 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $20 price target.
ChromaDex Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 129.89% HC Wainwright & Co. $6 → $6 Reiterates Buy → Buy 06/12/2024 129.89% Roth MKM $6 → $6
Beam Therapeutics Has Initiated A Search For A New CFO After Terry-Ann Burrell Shared Plans To Depart On August 9 To Join JPMorgan Chase
Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will
HC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $15 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Neutral and maintains $15 price target.
Inovio Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 30.1% HC Wainwright & Co. $15 → $15 Reiterates Neutral → Neutral 05/14/2024 73.46% Stephens &
Montrose Environmental Gr Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/15/2024 44.15% Needham $54 → $54 Reiterates Buy → Buy 05/09/2024 44.15% Needham $54 → $54 Reiterates